Today, on November 28, 2024, brings a fresh wave of funding announcements that underline the continued investor confidence in cutting-edge technologies and promising startup innovation. From early-stage ventures securing seed capital to growth-stage companies scaling globally, these funding rounds highlight the dynamic trends shaping the future of innovation.
Here's a concise roundup of today's funding announcements, detailing key players, amounts raised, and sectors making headlines. Whether you're an investor, entrepreneur, or industry watcher, this is your go-to resource for startup funding news. (Bookmark this page as we update it throughout the day with the latest announcements).
Roon Raises $15M to Transform Healthcare Information with Doctor-Created Video Content
Roon has successfully raised $15 million, co-led by Forerunner Ventures and FirstMark, with additional support from Sequoia Capital and TMV, achieving a valuation of $68 million. The platform aims to provide medically accurate information through videos created by physicians on various health issues.
With over 16,000 videos covering conditions like ALS and PCOS, Roon allows doctors to share their expertise directly with patients. Although Roon has yet to finalize its revenue model, investor Eurie Kim emphasizes the importance of trust and engaging content in developing a loyal user base.
Eyewa Secures $100M Funding to Expand Eyewear Stores in the Middle East
Eyewa has successfully raised $100 million in its Series C funding round, led by General Atlantic, bringing its total funding to $130 million since its inception in 2017. The financing will facilitate the addition of 100 new stores in six countries.
Other participants in the funding round include Badwa Capital and Turmeric Capital. Eyewa, which operates 150 stores, aims to enhance its growth trajectory within the expanding eyewear market in the Middle East.
Allink Biotherapeutics Secures $42M in Series A Funding for ADC Development
Allink Biotherapeutics completed a $42 million Series A financing round. The round was led by Lanchi Ventures with participation from Yuanbio Venture Capital, Legend Capital, C&D Emerging Industry Equity Investment, Gaorong Ventures, and Med-Fine Capital. The funding will support the advancement of their bispecific antibody and ADC therapeutics and global Phase I/II clinical programs.
Founded in 2023, Allink Biotherapeutics focuses on pioneering innovative therapeutics in the oncology and immunology spaces, leveraging its proprietary technologies and aiming to address unmet medical needs worldwide.
Volter Secures $3.2 Million for Rooftop Solar Monetisation
Volter, a provider of an operating system for rooftop solar products, has raised $3.2 million in pre-seed funding led by Transition, with participation from Seedcamp and Neptunia, a prominent real estate investor. The funds will support the development of its platform, which offers automated billing, customized insights, installation proposals, real-time performance monitoring, and benchmarking. The company also plans to expand its operations into a new European market.
With this funding, Volter aims to grow its team and prepare for significant expansion in 2025. The company’s platform is positioned to address the rising demand for renewable energy integration in commercial and industrial properties by providing tools to manage and scale onsite renewable energy systems. Future plans include expanding into energy services such as battery integration, energy optimization, and renewable energy brokerage.
/dev/agents Raises $56M Seed Round to Build AI Operating System
/dev/agents, co-founded by former Google executives, has raised $56 million in a seed round led by Index Ventures and co-led by CapitalG, with participation from Conviction Capital and tech leaders like Andrej Karpathy and Andy Rubin.
The funding values the startup at $500 million. The company aims to develop a cloud-based operating system for AI agents that facilitates multi-step tasks without user supervision, potentially revolutionizing the way AI interacts with the world.
